Syncromune®

📍 Fort Lauderdale, United States🗓 Founded 2020👥 18 employees💰 Last funded Oct 2022
Biotechnology Research🌐 syncromune.com
Website LinkedIn
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a personalized in situ therapy that combines partial tumor oncolysis and a multi-target biologic drug. The novel SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2020
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in Syncromune®?
Syncromune® has 1 investors on record on gritt.io, including 1 early-stage backers.
When did Syncromune® last raise funding?
The most recent investment in Syncromune® recorded on gritt.io was in October 2022.
When was Syncromune® founded?
Syncromune® was founded in 2020.
What industry is Syncromune® in?
Syncromune® operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Syncromune® based?
Syncromune® is headquartered in Fort Lauderdale, United States.